Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review

Zhang, Fuhong; Chen, Xiaowan; Xi, Kehu; Qiu, Zhiqiang; You-hu, Wang; Gui, Yan; Hou, Yun; Chen, Kangbing; Zhang, Xiaobing

doi:10.2147/ott.s184303

Cited by 5 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is worth noting that increasing evidence has indicated the wild functions by which lncRNAs accelerate or inhibit the glioma tumourigenesis . On the other hand, lncRNAs also could function as a promising prognostic marker in glioma …”

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Liu

Yang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Mounting evidence suggests the vital roles of long noncoding RNA (lncRNAs) in the glioma. However, the role of LINC00511 in gliomagenesis is still uncovered. Here, in this study, we aim to investigate the effects of LINC00511 on the glioma cancer phenotype and its deepgoing mechanism. Results indicated that LINC00511 was up‐regulated in glioma tissues and cell lines, moreover its overexpression positively correlated with the poor prognosis and advanced pathological stages. For the upstream regulation, LINC00511 was epigenetically up‐regulated by transcription factor specificity protein 1 (SP1). Gain and loss of functional experiments demonstrated that LINC00511 promoted the proliferation and invasion of glioma cells in vitro. The knockdown of LINC00511 repressed the tumour growth in vivo. Mechanistically, LINC00511 positively regulated the CCND2 expression via competitively sponging with miR‐124‐3p. Overall, our finding illuminates that LINC00511 is induced by SP1 and accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis, constructing the SP1/LINC00511/miR‐124‐3p/CCND2 axis.

show abstract

Section: Discussionmentioning

confidence: 99%

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Liu

Yang

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Differential expression of HAGLR was upregulated in HCC [ 40 , 41 ]. Mounting evidence suggests that high expression of HAGLR is related to clinicopathological features such as tumor size, lymph node metastasis, differentiation, TNM stage, and prognosis [ 42 , 43 ]. LINC02202 can regulate the expression of PIK3R1 and FOXO1 genes in PI3K signaling pathway [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma

Chen

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Background. As the most common hepatic malignancy, hepatocellular carcinoma (HCC) has a high incidence; therefore, in this paper, the immune-related genes were sought as biomarkers in liver cancer. Methods. In this study, a differential expression analysis of lncRNA and mRNA in The Cancer Genome Atlas (TCGA) dataset between the HCC group and the normal control group was performed. Enrichment analysis was used to screen immune-related differentially expressed genes. Cox regression analysis and survival analysis were used to determine prognostic genes of HCC, whose expression was detected by molecular experiments. Finally, important immune cells were identified by immune cell infiltration and detected by flow cytometry. Results. Compared with the normal group, 1613 differentially expressed mRNAs (DEmRs) and 1237 differentially expressed lncRNAs (DElncRs) were found in HCC. Among them, 143 immune-related DEmRs and 39 immune-related DElncRs were screened out. These genes were mainly related to MAPK cascade, PI3K-AKT signaling pathway, and TGF-beta. Through Cox regression analysis and survival analysis, MMP9, SPP1, HAGLR, LINC02202, and RP11-598F7.3 were finally determined as the potential diagnostic biomarkers for HCC. The gene expression was verified by RT-qPCR and western blot. In addition, CD4 + memory resting T cells and CD8 + T cells were identified as protective factors for overall survival of HCC, and they were found highly expressed in HCC through flow cytometry. Conclusion. The study explored the dysregulation mechanism and potential biomarkers of immune-related genes and further identified the influence of immune cells on the prognosis of HCC, providing a theoretical basis for the prognosis prediction and immunotherapy in HCC patients.

show abstract

“…222, Tian shui South Road, Cheng guan District, Lanzhou 730000, China. 4 Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China. 5 School of Clinical Medicine, Ningxia Medical University, Yinchuan, China.…”

Section: Authors' Contributionsmentioning

confidence: 99%

“…Despite rapid developments in medical technology and the increasing number and sophistication of treatment methods for tumors, the overall prognosis of cancer remains poor. One of the main reasons for this poor overall prognosis is the lack of specific markers for tumor diagnosis; thus, when a patient is diagnosed with cancer, it has usually progressed to the middle and late stages [ 4 ]. As a consequence of this delay in diagnosis, the optimal opportunity to treat cancer is usually lost.…”

Section: Introductionmentioning

confidence: 99%

“…Our understanding of the role of lncRNAs in the progression and suppression of multiple tumors has resulted in novel opportunities to improve the diagnosis and treatment of malignancies [ 17 , 18 ]. Meta-analyses revealed that HOXD-AS1[ 4 ], PODXL [ 19 ], and TP73-AS1 [ 20 ] were associated with the clinicopathological characteristics and prognosis of tumors. LncRNA prostate cancer-associated transcript 6 (PCAT6), which was first identified in keratinocytes, indirectly activates the Wnt/β-catenin pathway by interacting with KLHL12 in cervical cancer cells [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis

et al. 2021

View full text Add to dashboard Cite

Background LncRNA prostate cancer-associated transcript 6 (PCAT6) has been reported to be dysregulated in several cancers and is associated with tumor progression. Here, we have performed a meta-analysis to assess the general prognostic role of PCAT6 in malignancies. Methods Four public databases (Embase, Pubmed, Web of Science, Cochrane Library) were used to identify eligible studies, then data was extracted and associations between prognostic indicators and clinical characteristics were combined to estimate hazard ratio (HR) or odds ratio (OR) with a 95% confidence interval (CI). Publication bias was measured using the Begg's test, and the stability of the combined results was measured using sensitivity analysis. Subsequently, results were validated using Gene Expression Profiling Interactive Analysis (GEPIA) and the National Genomics Data Center (NGDC). Results Ten studies were considered eligible for inclusion. In total, 937 patients and eight types of cancer were included. Our results revealed that overexpression of PCAT6 was significantly associated with a shorter OS (HR = 1.82; 95% CI, [1.40, 2.38]; P < 0.0001) and progression-free survival (PFS) (HR = 1.66; 95% CI, [1.22, 2.25]; P < 0.0001) in cancer patients, and that PCAT6 overexpression was significantly associated with individual tumor clinicopathological parameters, including TNM stage (OR = 0.29; 95% CI, [0.09, 0.94]; P = 0.04), gender (OR = 1.84; 95% CI, [1.31, 2.59]; P = 0.0005), and whether the tumor was metastatic (OR = 5.02; 95% CI, [1.36, 18.57]; P = 0.02). However, PCAT6 overexpression was not correlated with patient age and tumor differentiation. PCAT6 expression was significantly up-regulated in four types of cancer, which was validated using the GEPIA cohort. Combining OS and disease-free survival (DFS) of these four types of cancer revealed a shorter OS and DFS in patients with PCAT6 overexpression. PCAT6 expression in various types of cancer was also validated in NGDC. A total of eight cancers were analyzed and PCAT6 was highly expressed in all eight cancers. Further functional predictions suggest that PCAT6 is correlated with tumor prognosis, and that PCAT6 may be useful as a new tumor-specific marker. Conclusions LncRNA PCAT6 is highly expressed in multiple cancer types and its upregulation was significantly associated with patient prognosis and poorer clinical features, thereby suggesting that PCAT6 may be a novel prognostic factor in multiple cancer types.

show abstract

Long noncoding RNA HOXD-AS1 in various cancers: a meta-analysis and TCGA data review

Cited by 5 publications

References 29 publications

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Long noncoding RNA LINC00511 induced by SP1 accelerates the glioma progression through targeting miR‐124‐3p/CCND2 axis

Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma

PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis

Contact Info

Product

Resources

About